Science Explorer Back to mapMap
Discussion
Institution · Cabinet Gastroenterology La Source-Beaulieu

Most cited papers from Cabinet Gastroenterology La Source-Beaulieu

Cabinet Gastroenterology La Source-Beaulieu

What are the most cited papers from Cabinet Gastroenterology La Source-Beaulieu?

The most cited paper from Cabinet Gastroenterology La Source-Beaulieu is "Microbial network disturbances in relapsing refractory Crohn’s disease" (Swiss IBD Cohort Investigators, Bahtiyar Yılmaz, Pascal Juillerat et al., 2019), with 463 citations. Next come "Viewpoint: Knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization" (103) and "Changes in Biosimilar Knowledge among European Crohn’s Colitis Organization [ECCO] Members: An Updated Survey" (98).

Showing 20 of 20 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Microbial network disturbances in relapsing refractory Crohn’s disease Swiss IBD Cohort Investigators, Bahtiyar Yılmaz, Pascal Juillerat et al. · Nature Medicine Open access 21 Jan 2019 463
2 Viewpoint: Knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization Silvio Danese, Gionata Fiorino, Pierre Michetti · Journal of Crohn s and Colitis Open access 5 Jul 2014 103
3 Changes in Biosimilar Knowledge among European Crohn’s Colitis Organization [ECCO] Members: An Updated Survey Silvio Danese, Gionata Fiorino, Pierre Michetti · Journal of Crohn s and Colitis 25 Apr 2016 98
4 Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort Yaël Abitbol et al. · Journal of Crohn s and Colitis 11 Jul 2016 72
5 Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease Eva Goncalves Serra et al. · Nature Communications Open access281 authors 21 Feb 2020 67
6 Calprotectin in Daily Practice: Where Do We Stand in 2017? Fabrizia D’Angelo, Christian P. Felley, Jean‐Louis Frossard · Digestion Open access 2017 59
7 Vedolizumab in Refractory Microscopic Colitis: An International Case Series Pauline Rivière, Andreas Münch, Pierre Michetti et al. · Journal of Crohn s and Colitis 14 Oct 2018 49
8 Inflammatory Articular Disease in Patients with Inflammatory Bowel Disease Saskia Ditisheim, Nicolas Fournier, Pascal Juillerat et al. · Inflammatory Bowel Diseases Open access 4 Aug 2015 45
9 Advances in vaccination againstHelicobacter pylori Dominique Velin, Pierre Michetti · Expert Review of Gastroenterology & Hepatology 30 Mar 2010 31
10 Toll-interacting Protein Modulates Colitis Susceptibility in Mice Michel H. Maillard, Hristina Bega, Holm H. Uhlig et al. · Inflammatory Bowel Diseases 26 Feb 2014 30
11 Loss of the branched-chain amino acid transporter CD98hc alters the development of colonic macrophages in mice Philipp Wuggenig et al. · Communications Biology Open access192 authors 18 Mar 2020 29
12 Structural Basis of Bone Fragility in Young Subjects with Inflammatory Bowel Disease Jessica Pepe, Sophie Zawadynski, François Richard Herrmann et al. · Inflammatory Bowel Diseases Open access 31 May 2017 24
13 On the selectivity of photodynamic therapy of choroidal neovascularization associated with age-related macular degeneration Hubert van den Bergh, Jean Pierre Ballini, Michel Sickenberg · Journal Français d Ophtalmologie Open access 2004 15
14 Place de l’échographie dans la prise en charge des endophtalmies Dominique Satger, Pierre Pégourié, J.P. Romanet et al. · Journal Français d Ophtalmologie Dec 2007 11
15 Potential to Improve Therapy of Chronic Myeloid Leukemia (CML), Especially for Patients with Older Age: Incidence, Mortality, and Survival Rates of Patients with CML in Switzerland from 1995 to 2017 Michael Daskalakis, Anita Feller, Jasmine Noetzli et al. · Cancers Open access 14 Dec 2021 10
16 Efficacité et tolérance d’un gel de carbomère fluide versus un gel de carbomère classique lors du traitement du syndrome sec F. Chiambaretta, P. Pouliquen, J.-M. Menerath et al. · Journal Français d Ophtalmologie Feb 2004 8
17 Efficacy of infliximab biosimilars in patients with Crohn's disease Pierre Michetti · The Lancet Open access Dec 2017 7
18 Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey Stephan R. Vavricka, Miloš Spasojevic, Gerhard Rogler et al. · Digestive Diseases Open access 2017 5
19 Medication Adherence in Inflammatory Bowel Disease in the Global ALIGN Study: Impact of Concerns and Perceived Necessity of Immunosuppressants, 5-Aminosalicylates, and Tumor Necrosis Factor Inhibitors Pascal Nurwakagari, Pierre Michetti, Laurent Peyrin‐Biroulet et al. · The American Journal of Gastroenterology Oct 2015 1
20 [Inflammatory bowel disease: what is the physician's role?]. Pierre Michetti · PubMed 26 Jan 2011 0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.